INTRODUCTION
Thoracic endovascular aortic repair (TEVAR) has emerged as an important treatment option for several thoracic aortic pathologies providing a significantly lower perioperative morbidity and mortality especially in high-risk patients. 1e4 Despite the evolution of TEVAR since its FDA approval in 2005, achieving safe and adequate access for stent graft introduction remains a critical intraoperative issue. Transfemoral route for device delivery remains the conventional procedure with feasibility in 70% of cases 5, 6 but in a significant number of patients, occlusive iliac disease, iliac tortuosity and small vessel caliber precludes trans-femoral approach. This issue is most commonly addressed through the use of a retroperitoneal iliac conduit. In the multicenter TAG thoracic endoprosthesis (W. L. Gore and Assoc, Flagstaff, Ariz) trial and in an international survey of physicians performing TEVAR, conduits were needed because of access-related issues in 15% of patients. 2, 3 Conduit or bypass for vascular access has become part of the standard procedure and serves significantly to expand the subset of patients who undergo TEVAR. To access continuing medical education questions on this paper, please go to www.vasculareducation.com and click on 'CME' Nevertheless, the effect of iliac conduits on the outcomes of TEVAR has not been thoroughly evaluated in a larger population. In our paper, we analyzed the perioperative morbidity and mortality associated with adjunctive iliac conduit placement compared with conventional transfemoral approach during TEVAR based on the American College of Surgeon National Surgical Quality Improvement Program (ACS NSQIP) database.
METHODS

Data source
ACS NSQIP is a risk-adjusted data collection mechanism that collects and analyzes clinical outcomes data. Participating hospitals use their collected data to develop quality initiatives that improve surgical care and to identify elements in provided healthcare that can be improved when compared with other institutions. Currently more than 300 institutions participate in this initiative. The ACS NSQIP collects data on a variety of clinical variables, including preoperative risk factors, intraoperative variables, and 30-day postoperative mortality and morbidity outcomes for patients undergoing major surgical procedures in both the inpatient and outpatient setting. A site's surgical clinical nurse reviewer (SCR) using a variety of methods, including medical chart abstraction, captures outcomes data. Vascular disease specific data as well as anatomic data are not included in the 2005e2010 ACS NSQIP database.
Data selection
Using this database, we identified patients undergoing elective TEVAR between 2005 and 2010.
Current Procedural Terminology (CPT, American Medical Association, Chicago, Ill) codes used were 33881 and 33880, which describe elective TEVAR and the "OTHER CPT" codes 34820 and 34833 used to describe conduit to facilitate TEVAR.
Risk factors and end-points
All risk factors available in the ACS NASQIP database were evaluated and compared between groups. The primary endpoint of the study was analysis of 30-day mortality. Secondary endpoints included postoperative morbidity, procedure-related complications and postoperative length of stay. Composite endpoints were created to facilitate a better understanding of the outcomes. Surgical complications (all surgical site infections, wound disruption, bleeding requiring transfusion, Graft/Prosthesis/Flap failure, peripheral nerve injury), renal complications (progressive renal failure, acute renal failure), pulmonary complications (pneumonia, unplanned intubation, respiratory insufficiency requiring ventilation for 48 h), any sepsis (SIRS, sepsis, septic shock), non-surgical complication (any complication except surgical complications), cardiovascular complications (pulmonary embolism, stroke/cerebrovascular event, cardiac arrest, myocardial infarction, deep vein thrombosis/ thrombophlebitis) were analyzed. The variable "graft failure" describes the mechanical failure of a stent graft or prosthesis requiring return to the operating room, interventional radiology, or a balloon angioplasty within 30 days of the operation.
Statistical analysis
Categorical data were described using absolute numbers and percent prevalence (%) in the study cohort. Continuous variables were presented as means (AEstandard deviation). Categorical variables were compared by use of the Chi square test or Fischer exact test for discrete values, while independent 2-sample T-tests were used for normally distributed continuous variables and the Wilcox rank sum test for nonnormally distributed continuous and ordinal variables.
Multivariable logistic regression models were used to assess the association between type of repair (TEVAR with conduit and TEVAR without conduit) and post-operative mortality while controlling for possible confounders. Confounders were identified by running regression models with type of repair and one additional preoperative risk factor or demographic variable at a time as predictors and seeing how the results differed from running a logistic model using type of repair alone. A change of more than 10% between the crude and adjusted odds ratio of type of repair was used as evidence that the covariate was a possible confounder. A final logistic regression model was run using type of repair groups and all confounders found in this way.
Patients of age >90 years were transformed into 90 in the database. A P value of less than 0.05 was considered the limit for statistical significance. Data were analyzed using SPSS Statistics Version 19.0 (SPSS, IBM Inc). Odds ratios (OR) are presented with 95% confidence intervals (CI).
RESULTS
In the 2005e2010 ACS NSQIP database we identified 1154 patients who underwent elective repair of their TAA with or without coverage of the left subclavian artery. 1037 patients did not require use of a conduit (Group A, 89.9%) while 117 did (Group B, 10.1%). Female patients required conduit in 15.1% of the cases while males in 5.7% (p < 0.001). The demographic data of the two groups are available in Table 1 . The two groups differed only with respect to history of cardiac surgery or intervention, which was higher in the non-conduit group, and smoking, which was more frequent in the conduit group.
Duration of the procedure was on average longer in the conduit group by 67 min (p < 0.001) and need for intraoperative transfusion was higher (p ¼ 0.013) ( Table 2) .
Patients undergoing TEVAR with use of a conduit had a significantly higher risk of surgical complications compared to patients without conduit (p ¼ 0.035) as well as a higher risk of any complication (p ¼ 0.025). Surgical site infections were however not significantly different between the groups and need for transfusion was the factor responsible for higher rate of surgical complications in the conduit group (p ¼ 0.003). Risk for pulmonary, renal, septic and cardiovascular complications did not significantly differ between groups ( Table 2 ). The complications of each group are presented in detail in the Appendix 1.
Thirty-day mortality was 12% for patients who required a conduit as an adjunctive procedure to TEVAR and 4.5% for patients without conduit (p ¼ 0.001). The multivariate analysis for mortality after controlling for relevant confounders, showed a 3.8 times higher risk of death for patients who had conduit placement (Table 3) . Mean postoperative length of stay in hospital was not significantly different among groups (p ¼ 0.247).
In the year 2005, there were only 6 patients with TEVAR entered in the ACS NSQIP database. Between 2006 and 2010 the use of conduits during TEVAR had a constantly declining rate resulting in a 6.5% use of iliac conduits in 2010, down from 17.9% in 2006 ( Fig. 1 ). 
DISCUSSION
The present paper addresses the influence of iliac conduit use on the outcomes of TEVAR. In an analysis of 1154 TEVAR patients who were entered over a 5-year period in the ACS NSQIP database, we could demonstrate that the use of conduits was independently associated with higher mortality even after controlling for relevant confounders as gender and intraoperative coverage of the left subclavian artery (Odds ratio 3.8). Although the groups of patients with and without conduit did not substantially differ with respect to risk factors, it was obvious that female patients were more likely to receive a conduit than males. Unfortunately data concerning the anatomy of the aortic arch that could lead to increased number of strokes and subsequent deaths are not captured in the ACS NSQIP database. Patients requiring conduit had a higher risk of bleeding and receiving intra-and post-operative blood transfusions. Interestingly there was no difference in wound infections as well as in renal, cardiovascular complications and the composite endpoint of pulmonary complications between groups, although patients with conduit had a greater reintubation risk in the early postoperative period. In this series patients receiving conduits had a slightly higher rate of cerebrovascular events (5.1% with conduits vs. 3.9% without conduits, p ¼ 0.01). The interpretation of these findings is a critical issue and extreme caution is warranted not to imply that the use of conduit itself is the cause of higher mortality.
Due to the nature of the database we can only speculate on how the use of conduits influences mortality during TEVAR. A major contributor to mortality could be the fact that patients undergoing TEVAR already have a restricted cardiac and respiratory function, so that a surgical procedure even in the form of a retroperitoneal approach could be relevant in overall outcome.
Another explanation could be of course that patients with challenging vascular access have on the whole a more challenging anatomy leading to more complications and/or mortality. These anatomic factors including the morphology of the arch are not captured in the ACS NSQIP database and this represents of course one of the database's limitations.
Despite technologic advances and device improvements, the large sheaths required during TEVAR, represent a significant limitation in the setting of heavily calcified or torturous iliac arteries. A variety of ancillary techniques used to facilitate device navigation are available including simple iliac artery angioplasty, retrograde external iliac artery endarterectomy, placement of a covered stent followed by controlled rupture of the iliac artery (endoconduit), and the construction of an open iliofemoral bypass conduit. 7e9 Data from single-and multi-centered studies report the incidence of access problems requiring use of open surgical iliac conduit at 9e21% of patients undergoing TEVAR. 2,4,10e12 Women are known to be associated with a higher risk of access site complications due to their smaller access vessel diameter and need of iliac conduits. 11, 13, 14 However association of outcome and use of iliac conduit was not specifically investigated irrespective of gender in these studies. Etezadi et al. 15 recently reviewed their experience with use of conduits in 133 consecutive patients but were not able to show a significantly worse outcome in the 19 patients requiring retroperitoneal iliac access.
Over the past five years, a significant reduction in the use of iliac conduits has occurred from 17.9% of elective TEVAR cases in 2006 down to 6.5% in 2010. The reason for this is likely due to the increasing use and experience with endovascular techniques such as the so called "paving and cracking" technique to overcome the issue of small and calcified iliac arteries. The use of endoconduits has been increasing during TEVAR after first description of the technique by Peterson and Matsumura in 2008. 16 The time point of introduction of this technique coincides with the decrease in the use of open surgical conduits via retroperitoneal access. This decreasing trend may also be associated with the experience gained in the field by vascular surgeons over the years, as well as by improved technology of the delivery sheaths, such as adding hydrophilic coating to the outside of the sheaths and making the sheaths more flexible. The hydrophilic coating has made the sheaths more lubricious allowing them the ability to more easily traverse narrowed, calcified iliac arteries, and the increased flexibility has permitted better navigation through tortuous vessels.
The introduction of devices with lower profile that would facilitate access to the target vessels without the use of endo-or conventional conduits has been eagerly anticipated. Most companies currently provide stent grafts that come with or require a sheath of 22 French (F) to introduce a stent graft of 31e34 mm of diameter and 24 F for larger diameter devices. The next generation of thoracic devices however is expected to decrease the crossing profile below the threshold of 22 F. The Zenith TX2 Low Profile device (Cook Medical, Indianapolis, IN) is currently under clinical trial and allows introduction of a 32 mm stent graft through an 18 F sheath.
LIMITATIONS
This is an observational study from a registry database. Limitations of the study mainly involve missing variables that are not captured in the ACS NSQIP database such as aneurysm specific characteristics as well as the fact that only patients who underwent open conduit are included. The ACS NSQIP database was created to report data collected from surgical patients in different specialties to enhance quality of care by providing data for comparison. Thus, limitations due to the database design are expected when a specific surgical entity and issue is addressed. Details on type of graft failure or reason for reintervention are not available. Data were collected from over 400 hospitals in the United States so that a uniform pattern of patient management, or indication for surgery and retroperitoneal conduit cannot be identified.
CONCLUSION
The use of iliac conduits to facilitate access for TEVAR is associated with higher surgical complications and mortality in comparison to patients who do not require conduits. Female patients more frequently require iliac conduits during TEVAR compared to men. This may contribute to the worse overall outcomes for women during TEVAR as described in industry-sponsored trials. The incidence of conduit use has decreased threefold in the last five years which may be in part due to the introduction of alternative interventional techniques such as the use of endoconduits. The current data, however, should not discourage vascular surgeons from using conduits to establish safe access, but rather make them aware of the higher associated morbidity and mortality rates. Technological advances in sheath manufacturing, such as hydrophilic coating, increased flexibility and reduced crossing profiles promise to simplify device delivery and reduce access-related complications. 
